How to appeal a UnitedHealthcare glaucoma (drops + procedures + surgery) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for glaucoma (drops + procedures + surgery)

Cited policy: UHC Selective Laser Trabeculoplasty (SLT) for Glaucoma / OHT (CPT 65855)

Diagnosis of POAG, pseudoexfoliation, pigmentary, or OHT meeting treatment threshold. Open angle on gonioscopy. Documented IOP not at target on or off medications, OR drop intolerance / non-adherence / preservative reaction. Bilateral allowed when both eyes meet criteria. Up to 2 SLT treatments per eye per 12 mo without escalation.

How UnitedHealthcare denies glaucoma (drops + procedures + surgery) — and how to counter it

Where UnitedHealthcare pushes back: 1) Drops not tried first; 2) Bilateral not medically necessary; 3) Repeat SLT before adequate trial of medical therapy.

Counter-arguments that hold up: LiGHT trial (Gazzard Lancet 2019;393:1505-1516 + 6-yr Ophthalmology 2022;130:139-151) — primary SLT non-inferior in IOP control with 69.8% drop- and surgery-free at 6 yr vs 18.0% in drops arm; less VF progression (16.9% vs 26.2% moderate/fast) and fewer trabeculectomies (13 vs 32). AAO POAG PPP 2020 lists SLT as FIRST-LINE option (Strong Recommendation, High Quality). LiGHT enrolled bilateral disease — bilateral SLT is appropriate. Document drop intolerance / OSD / adherence barriers / preservative reactions.

What UnitedHealthcare typically denies for glaucoma (drops + procedures + surgery)

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For glaucoma (drops + procedures + surgery), expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the glaucoma (drops + procedures + surgery) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Latanoprost (generic)
• Xelpros (BAK-free latanoprost)
• Travatan Z (travoprost)
• Lumigan (bimatoprost)
• Zioptan (tafluprost PF)
• Vyzulta (LBN)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.